A PPAR-alpha agonist and DPP-4 inhibitor mitigate adipocyte dysfunction in obese mice.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of molecular endocrinology"
DOI: 10.1530/jme-21-0084
Abstract: Obesity causes white and brown adipocyte dysfunction, reducing browning and stimulating whitening. Drugs that tackle adipocyte dysfunction through thermogenesis stimulation could be used to treat obesity. This study sought to address whether a combination of… read more here.
Keywords: combination; alpha agonist; dysfunction; adipocyte dysfunction ... See more keywords